Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2023-10-25 AGM Information
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting/Proxy Form 20 pages 902.1KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF 2023 ANNUAL GENERAL MEETING AND EXPLANATORY STATEMENT OF PHARMAXIS LTD' and details the arrangements for the 2023 Annual General Meeting (AGM) including date, time, virtual meeting instructions, proxy voting procedures, and the agenda items such as adoption of the remuneration report, re-election of directors, approval of performance rights grants, and change of company name. It includes detailed resolutions to be voted on at the AGM and instructions for shareholders. The document is a notice and explanatory statement for the AGM, not the actual meeting materials or minutes, nor a report of financial results or management discussion. It is not a report publication announcement since it contains substantive meeting details and resolutions. Therefore, the document fits the category of AGM Information (AGM-R).
2023-10-25 English
Annual Report to shareholders 70 pages 1.4MB
Annual Report Classification · 100% confidence The document is titled 'STATUTORY ANNUAL REPORT' for the year ended 30 June 2023 for Pharmaxis Ltd. It contains detailed sections including Directors' Report, Remuneration Report, Corporate Governance, Senior Management, Operating and Financial Review and Prospects, and Financial Statements with notes. The presence of comprehensive financial statements, directors' declarations, and an independent auditor's report confirms this is a full annual report. The length of the document (15,000 characters) and the detailed content indicate it is the actual report, not just an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2023-10-25 English
Corporate Governance Statement 19 pages 248.7KB
Governance Information Classification · 100% confidence The document is titled 'Copy of Corporate Governance Statement – 2023' and contains detailed descriptions of the company's corporate governance framework, board structure, policies, and practices. It references the ASX Corporate Governance Principles and Recommendations and discusses board composition, director independence, committee charters, diversity policies, and performance evaluations. There is no financial data, earnings information, or audit results presented. The content is focused on governance practices and policies rather than financial reporting or announcements. Therefore, this document fits the category of Governance Information (CGR). The document length (15,000 characters) and detailed content confirm it is a full governance statement, not a brief announcement or summary.
2023-10-25 English
Appendix 4G 14 pages 270.4KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G' and references the ASX Listing Rules, specifically Listing Rule 4.10.3 and 4.7.4, which relate to corporate governance disclosures. It includes a key to disclosures against the Corporate Governance Council Principles and Recommendations and confirms that the corporate governance statement is available on the company's website rather than within the annual report. The document is a form used to verify compliance with corporate governance disclosure requirements and is not the corporate governance statement itself nor the annual report. It is a regulatory filing that accompanies the annual report to the ASX but does not contain substantive financial data or detailed governance reports. Therefore, it fits best under Regulatory Filings (RNS).
2023-10-25 English
Pharmaxis Completes Sale of Mannitol Business 2 pages 193.8KB
Capital/Financing Update Classification · 95% confidence The document is a media release dated 19 October 2023 announcing the completion of the sale of Pharmaxis Ltd's mannitol respiratory business to Arna Pharma. It details the transaction, operational handover, cost savings, and background information about both companies. There is no financial statement, regulatory filing, or detailed financial analysis included. The document is an announcement of a capital transaction (sale of a business unit) and restructuring, which fits the category of Capital/Financing Update (CAP). The document length is over 6000 characters, indicating it is a full announcement rather than a brief note or report publication announcement. Therefore, the appropriate classification is CAP with high confidence.
2023-10-18 English
Investor Presentation 33 pages 2.2MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and contains detailed information about the company's strategy, clinical programs, management team, scientific data, and commercial opportunities. It includes forward-looking statements, clinical trial updates, and financial implications but does not present formal financial statements or regulatory disclosures typical of annual or quarterly reports. The length is substantial (15,000 characters), and the content is consistent with a presentation aimed at investors to inform them about the company's business and prospects. Therefore, this document fits the category of an Investor Presentation (IP).
2023-10-16 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.